Applications of Chukrasone A in medicines used for treating rheumatoid arthritis

An arthritis and rheumatoid technology, applied in the application field of Chukrasone A in the treatment of rheumatoid arthritis drugs, can solve the problems of poor action selectivity, ulcers, easy to induce infection, etc., and achieve outstanding substantive characteristics and strong inhibitory activity Effect

Inactive Publication Date: 2013-11-06
单秋丽
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) Gastrointestinal mucosa leads to peptic ulcer, which has poor selectivity and is easy to induce infection, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of Chukrasone A in medicines used for treating rheumatoid arthritis
  • Applications of Chukrasone A in medicines used for treating rheumatoid arthritis
  • Applications of Chukrasone A in medicines used for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Embodiment 1: the preparation of the compound Chukrasone A tablet involved in the present invention:

[0013] Take 20 grams of compound Chukrasone A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press.

Embodiment 2

[0014] Embodiment 2: the preparation of the compound Chukrasone A capsule involved in the present invention:

[0015] Get 20 grams of compound Chukrasone A, add conventional auxiliary materials for preparing capsules such as 180 grams of starch, mix well, and pack into capsules to make 1000 tablets.

[0016] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0017] Experimental example 1, the influence of Chukrasone A of the present invention on rat adjuvant arthritis

[0018] Grind Mycobacterium casei (Difco) and mix it with liquid paraffin to make 10mg / ml, and make Freund's complete adjuvant after autoclaving. Male SD rats were intradermally injected with 50ul of the above-mentioned adjuvant in the right hind paw, and at the same time, injected 50ul intradermally at the tail about 3cm away from the base of the tail. The difference of , represents the degree of swelling. On the 16th day after the injection of the adjuvant, the swelling of the left hind foot of the rats was obvious. The rats were divided into groups according to the degree of swelling and body weight. The experimental group was orally given Chukrasone A 5.0, 10.0, 20.0 mg / kg of the present invention, and the positive control group was orally given diclofenac 10 mg / kg, the control group was given equal volume of distilled water, once a day, for 7 consecutive days,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses Chukrasone A used for treating immunity inflammation. When seldane and diclofenac sodium are used as control samples, curative effect of Chukrasone A is clear in preparation of medicines used for treating rheumatoid arthritis. The applications of Chukrasone A in preparation of medicines used for treating rheumatoid arthritis is discloses for the first time. The molecular skeleton is novel, so that the inhibitory activity on rheumatoid arthritis is surprisingly strong, and it is impossible to estimate the inhibitory activity according to the inhibitory activities of other compounds. Chukrasone A possesses outstanding substantiality, and the applications of Chukrasone A in prevention and cure of rheumatoid arthritis possess significant advantages.

Description

technical field [0001] The invention relates to the application of Chukrasone A in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis is a clinical common disease and frequently-occurring disease. Rheumatoid arthritis belongs to autoimmune disease and belongs to the category of immune inflammation. At present, for rheumatoid arthritis, non-steroidal anti-inflammatory drugs (diclofenac, aspirin, etc.) and immunosuppressants (6-mercaptopurine, etc.) Gastrointestinal mucosa leads to peptic ulcer, which has poor selectivity and is easy to induce infection. Therefore, compounds with well-defined components, controllable quality, safety and high efficiency have potential value in the development of drugs for rheumatoid arthritis. [0003] The compound Chukrasone A involved in the present invention is published in 2012 (Liu, H. B. et al., 2012. Chukrasones A and B: Potential Kv1.2 Potassium Channel Blockers with New ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/585A61P29/00A61P19/02
Inventor 丁圣雨
Owner 单秋丽
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products